编号：2023-001 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □电话会议 □其他 参与单位名称 及人员姓名 科拓生物2022年度业绩说明会采用网络远程方式进行，面向全体投资 者。 时间 2023 年 4 月 27 日 15:00-17:00 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏目 公司接待人员 姓名 董事长：孙天松女士 总经理：刘晓军先生 副总经理、财务总监：余子英先生 副总经理、董事会秘书：张凌宇先生 独立董事：刘惠玉女士 投资者关系活动 主要内容介绍 1、公司最近还有增发计划？资金面紧张？ 答：尊敬的投资者您好，公司提请股东大会授权董事会办理以简易 程序向特定对象发行股票相关事宜尚需公司 2022 年年度股东大会审议， 董事会将根据公司的融资需求在授权期限内审议具体发行方案，报请深 圳证券交易所审核并经中国证监会注册后方可实施，存在不确定性。公 司将及时履行信息披露义务，敬请广大投资者注意投资风险。感谢您的 关注！ 证券代码：300858 证券简称：科拓生物 北京科拓恒通 ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥369.17 million, representing a 1.25% increase compared to ¥364.62 million in 2021[23]. - The net profit attributable to shareholders for 2022 was approximately ¥109.89 million, a slight increase of 0.32% from ¥109.54 million in 2021[23]. - The net profit after deducting non-recurring gains and losses increased by 18.08% to approximately ¥98.08 million in 2022, compared to ¥83.06 million in 2021[23]. - The net cash flow from operating activities for 2022 was approximately ¥148.46 million, marking a significant increase of 34.63% from ¥110.27 million in 2021[23]. - Total assets at the end of 2022 reached approximately ¥1.79 billion, a 72.05% increase from ¥1.04 billion at the end of 2021[23]. - The net assets attributable to shareholders increased by 75.37% to approximately ¥1.70 billion at the end of 2022, compared to ¥967.40 million at the end of 2021[23]. - The company reported a basic earnings per share of ¥0.74 for 2022, unchanged from 2021[23]. - The company achieved a year-on-year revenue growth of 1.25% and a net profit growth of 0.32%, maintaining overall performance stability despite economic pressures[54]. - In 2022, the company's total revenue reached ¥369,165,339.19, with a gross margin of 51.98%, showing a year-on-year increase of 1.25%[72]. - The edible probiotic product business generated revenue of 139.53 million yuan, representing a significant year-on-year growth of 87.09%, driven by increasing consumer awareness of health[88]. - The compound food additive business revenue was 172.70 million yuan, a decline of 27.70% year-on-year, primarily due to market demand fluctuations[90]. Market Position and Strategy - The company aims to increase its market share in the domestic probiotic raw material market, which is currently dominated by foreign brands like DuPont and Chr. Hansen[39]. - The company has a competitive advantage in the domestic market due to its proprietary strains and intellectual property, positioning it well against foreign competitors[40]. - The company is focusing on the development of postbiotics, which are gaining popularity and showing explosive growth potential in the health industry[40]. - The company aims to become "China's leading probiotic brand and a leader in food ingredients," focusing on a comprehensive probiotic product chain[54]. - The company is actively expanding its C-end business, focusing on differentiated marketing strategies across various channels[89]. - The company is focused on expanding its market presence and enhancing its product offerings, particularly in the field of food additives and biotechnology[182]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of CNY 500 million allocated for this purpose[184]. Research and Development - The company invested 22.09 million yuan in R&D, conducting 39 projects and obtaining 7 new domestic invention patents during the reporting period[91]. - The company has established a large lactic acid bacteria resource library with over 20,000 strains, including more than 120 industrialized probiotic strains[81]. - The company is actively engaged in product and technology development, leveraging its strain resource library and R&D platform for continuous innovation[66]. - The company is focusing on improving the flavor and stability of its products through technological advancements in fermentation processes[112]. - The company is enhancing its research and development efforts to adapt to industry demands and improve product offerings, including yogurt fermentation agents and postbiotics[150]. - The company has completed the screening of strains for a new mouthwash-specific lactic acid bacteria product, expanding its product line[113]. - The company is developing a composite probiotic product for the auxiliary treatment of type 2 diabetes, with clinical efficacy confirmed[113]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements and future plans[4]. - The company faces various risks and has outlined measures to address them in the management discussion section[4]. - The company is addressing high customer concentration risks by diversifying its revenue sources into plant protein beverages and baked goods[155]. Corporate Governance - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, and operations, ensuring a complete business system[172]. - The company has an independent financial accounting system and does not share bank accounts with its controlling shareholders[173]. - The company has implemented a restricted stock incentive plan, with key executives receiving allocations of 24,000 shares each for Ma Jie, Yu Ziying, and Zhang Lingyu, and 38,400 shares for Qimu Gesu and Zhang Jianjun[178]. - The company has appointed independent directors to ensure governance and oversight, with each receiving CNY 100,000[194]. - The company continues to expand its management team with experienced professionals from various sectors[195]. - The company has a structured remuneration decision-making process involving shareholder and board approvals[193]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 30% based on new product launches and market expansion strategies[165]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[165]. - The company aims to launch three new products in 2023, which are expected to contribute an additional 200 million RMB in revenue[165]. - The company plans to increase its marketing budget by 30% in 2023 to strengthen brand presence and customer engagement[184].

北京科拓恒通生物技术股份有限公司 2023 年第一季度报告 证券代码：300858 证券简称：科拓生物 公告编号：2023-032 北京科拓恒通生物技术股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | (%) | | 营业收入(元) | 72,147,839.92 | 86.068.078.55 | -16.17% | | 归属于上市公司股东的净利 | 20.051.536.52 | 23.445.594.81 | -14.48% | | 润(元) | | | | | 归属于上市公司股东的扣除 非经常性损益的净利润 | 17.722.508.42 | 19.554.907.86 | -9.37% | | (元) | | | | | 经营 ...

证券代码：300858 证券简称：科拓生物 公告编号：2023-034 为进一步提高公司治理水平，便于广大投资者更全面、深入地了解公司情况， 公司定于2023年4月27日（星期四）下午15:00—17:00在深圳证券交易所"互动易" 平台"云访谈"栏目举行2022年年度报告网上业绩说明会（以下简称"本次说明 会"），现将有关事项公告如下： 本次说明会将采用网络远程的方式举行，投资者可登陆深圳证券交易所"互 动易"平台（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次会议。 出席本次业绩说明会的人员有：公司董事长孙天松女士，总经理刘晓军先生， 副总经理、财务总监余子英先生，副总经理、董事会秘书张凌宇先生，独立董事 刘惠玉女士。 为充分尊重投资者、提升交流的针对性，现就公司本次说明会提前向投资者 公开征集问题。投资者可提前登录"互动易"平台（http://irm.cninfo.com.cn）"云 访谈"栏目进入公司本次说明会页面进行提问。届时公司将在本次说明会上对投 资者普遍关注的问题进行回答。期间，投资者仍可登陆活动界面进行互动提问。 北京科拓恒通生物技术股份有限公司 关于举行 2 ...

Financial Performance - Revenue and non-GAAP net profit increased in the first half of the year, but net profit slightly decreased due to the impact of the pandemic [2][3] - Non-recurring gains and losses decreased in the first half, but recovery began in May and is not expected to affect annual performance [2][3] Strategic Partnerships - The strategic cooperation agreement with Mengniu is expected to be renewed for another three years by the end of the year [3] - The company has partnered with Jiangzhong Pharmaceutical and Shangyao Xinyi for its probiotic business [3] Product Development and Market Strategy - The company's Jinhua Galaxy strain factory meets the production conditions for health supplements, and the company has started laying out in this area [3] - The company is focusing on both B2B and B2C markets for its probiotic business, leveraging partnerships with large food and pharmaceutical companies for B2C product development [4] - The company is conducting clinical trials and research to back the efficacy of its probiotic products [4] Operational Details - The company implements a policy of payment before delivery for its probiotic products sold through offline distributors [4] - Some R&D personnel hold shares in the company through partnerships [4] - The Beijing compound food additive factory has a designed single-shift capacity of 3,500 tons, with the ability to increase shifts to meet demand [4] Industry Insights - Developing probiotic strains requires significant investment in time and resources, and internationally recognized strains have undergone extensive research and clinical trials [3][4]

Group 1: Company Overview and Market Position - The company has been focusing on the research and development of probiotics, particularly in the area of Helicobacter pylori, which has gained significant market attention recently [2][3] - Since its establishment, the company has relied on its proprietary strain resources and has conducted over 50 clinical trials in collaboration with top-tier hospitals, with 29 trials completed [3] - The company aims to achieve technological breakthroughs and deliver products that benefit consumers and society [3] Group 2: Product Development and Clinical Trials - The company has identified several key probiotic strains, including Lactobacillus Zhang and Bifidobacterium V9, and has validated their beneficial functions through large-scale clinical trials [3] - The company has expanded into the probiotic pharmaceutical sector since 2019, elevating its research efforts [3] - The focus on Helicobacter pylori will continue, with ongoing product design and research efforts [3] Group 3: Investor Insights and Market Growth - The company believes it is on par with international probiotic companies in terms of research and development, despite starting later [3] - The domestic probiotic market is experiencing rapid growth, with significant market share still held by multinational corporations [3] - As the only publicly listed probiotic company in China, the company is confident in the future growth of its probiotic product segment [3]

Group 1: Impact of COVID-19 - The company faced challenges in logistics and customer expansion due to severe COVID-19 outbreaks in the first half of the year, although production continued at its bases in Beijing, Jinhua, and Hohhot [1] - Improvement in operations was noted starting from June [1] Group 2: Probiotic Market Overview - The overall market size for probiotic products in China was approximately 879.8 billion yuan in 2020 [1] - China has surpassed Italy to become the second-largest probiotic consumer market globally, with an annual growth rate of 11-12% [1] - The market shows significant potential for growth supported by policy and industry regulations [1] Group 3: Applications and Sales Channels - Probiotics have a wide range of applications in dairy products, healthcare, functional foods, snacks, and personal care [2] - The company has multiple proprietary brands, including "Yishiyou," "Yishenghemei," and "Baiyiduo," with "Yishiyou" being self-operated while others are authorized to distribution teams [2] - A new clinical nutrition brand "Yiyongjun" was developed and exclusively authorized to Wuhan Yongjun Biotechnology Co., Ltd. for promotion in hospitals, pharmacies, and health management institutions [2]

北京科拓恒通生物技术股份有限公司 2022 年第三季度报告 证券代码：300858 证券简称：科拓生物 公告编号：2022-072 北京科拓恒通生物技术股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 北京科拓恒通生物技术股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 107,242,551.93 ...

Financial Performance - The company reported a total revenue of RMB 300 million for the first half of 2022, representing a year-on-year increase of 15%[16]. - The net profit attributable to shareholders for the same period was RMB 50 million, up 20% compared to the previous year[16]. - The company's operating revenue for the current period is ¥156,856,172.93, a decrease of 6.25% compared to ¥167,306,738.39 in the same period last year[23]. - The net profit attributable to shareholders of the listed company is ¥44,820,865.97, reflecting a slight increase of 0.52% from ¥44,591,078.01 in the previous year[23]. - The company achieved a revenue of 156.86 million yuan in the first half of 2022, a year-on-year decrease of 6.25%[46]. - The net profit attributable to the parent company was 44.82 million yuan, reflecting a slight increase of 0.52% year-on-year[46]. - The company's total revenue for the first half of 2022 was approximately ¥156.86 million, a decrease of 6.25% compared to the same period in the previous year[74]. - The company reported a total profit of 204.5 million yuan for the first half of 2022[166]. User Engagement and Market Expansion - User data indicated a growth in active users by 25%, reaching a total of 1.5 million active users by June 30, 2022[16]. - Future guidance estimates a revenue growth of 10-15% for the second half of 2022, driven by new product launches and market expansion[16]. - Market expansion efforts include entering two new provinces, aiming for a 30% increase in market share by the end of 2023[16]. - The company is targeting a 15% increase in export sales by entering new international markets in 2023[63]. - The company plans to expand its product line, introducing three new animal feed products by Q3 2022, targeting a 10% market share increase in the livestock sector[63]. Research and Development - The company plans to invest RMB 100 million in R&D for new product development in the next fiscal year[16]. - The R&D budget for 2023 is set at 50 million RMB, representing a 20% increase from 2022, aimed at enhancing product efficacy and safety[63]. - The company has filed for two new domestic invention patents during the reporting period, enhancing its R&D capabilities[49]. - The company is focusing on developing innovative probiotic products to meet increasing consumer demand in the health sector[16]. - The company is focusing on both B-end and C-end markets, with a differentiated marketing strategy for various channels[47]. Product Development and Innovation - The company aims to leverage its proprietary strains to replace imported probiotics, capitalizing on the unique gut microbiome of the Chinese population[37]. - The company’s plant-based microbial preparations are designed to improve soil health and enhance crop yields, addressing the growing demand for sustainable agricultural practices[43]. - The company is focused on developing probiotic strains and related technologies, aiming for long-term stable customer relationships and maximizing product sales[68]. - The company emphasizes the development of new probiotic products and formulations to meet specific consumer needs and market demands[58]. - The company is actively developing food formulas and corresponding technologies in the plant protein beverage and baked goods sectors to diversify its revenue sources[126]. Strategic Partnerships and Collaborations - The company has established deep R&D collaborations with leading enterprises in the food, pharmaceutical, and daily chemical sectors, enhancing its strategic partnerships[68]. - The company signed a strategic cooperation agreement with Mengniu Dairy for a three-year term, focusing on procurement and product supply[180]. - The company has established a partnership with Jiangzhong Pharmaceutical for the development of probiotics, with a contract signed on October 27, 2021[182]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product portfolio[182]. Market Trends and Industry Insights - The probiotics market is rapidly growing, with increasing applications in infant formula, yogurt, and beverages, indicating a trend towards expanding customer bases in the food and beverage sector[34]. - The global probiotic market is expected to grow from $61.1 billion in 2021 to $91.1 billion by 2026, at a CAGR of 8.3%[36]. - The domestic probiotic market in China was approximately ¥879.8 billion in 2020, with a growth rate of 11-12% annually[36]. - The yogurt product market in China saw a recovery in 2021, with a market size exceeding ¥1500 billion, representing a year-on-year growth of 8.6%[40]. Financial Management and Investments - The company plans to raise up to 700 million yuan through a targeted stock issuance, with 620 million yuan allocated for the food sector's R&D and production base project[50]. - The company has a commitment to produce 10,000 tons of food additives annually, with an investment of CNY 11,181,000, which is currently at 0% progress[111]. - The company has a total of CNY 32,129,100 in cumulative changes to the purpose of raised funds, indicating a significant portion of funds have been reallocated[109]. - The company has entrusted a total of 51,800 million yuan in financial management, with 30,450 million yuan currently invested[116]. Corporate Governance and Compliance - The company has established a sound internal control system and optimized its governance structure in compliance with relevant laws and regulations[152]. - The company strictly adheres to labor laws, ensuring employee rights and benefits, including contributions to social insurance[153]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[150]. - The company has implemented measures to reduce carbon emissions but did not disclose specific details[150]. Shareholder and Stock Management - The company completed the registration of 393,600 shares for the first vesting period of the 2021 restricted stock incentive plan, with the listing date on June 13, 2022[147]. - The total number of shares increased from 148,531,845 to 148,925,445, reflecting an increase of 393,600 shares due to the first vesting period of the 2021 restricted stock incentive plan[195]. - The company’s stock incentive plan was approved in board meetings held on April 24, 2022, indicating a strategic focus on employee retention and motivation[195]. - The company plans to release certain restricted shares on July 27, 2023, which may impact future shareholder dynamics[198].

Financial Performance - The company's revenue for Q1 2022 was ¥86,068,078.55, representing a 6.63% increase compared to ¥80,716,575.97 in the same period last year[3] - Net profit attributable to shareholders was ¥23,445,594.81, an increase of 8.75% from ¥21,558,322.68 year-on-year[3] - Total operating revenue for Q1 2022 was CNY 86,068,078.55, an increase of 6.7% compared to CNY 80,716,575.97 in Q1 2021[23] - Net profit for Q1 2022 reached CNY 23,445,594.81, representing a growth of 8.8% from CNY 21,558,322.68 in Q1 2021[24] - The company achieved a total profit of CNY 28,031,886.15 in Q1 2022, compared to CNY 25,835,238.25 in Q1 2021, indicating an increase of 8.4%[24] Cash Flow - The net cash flow from operating activities reached ¥36,584,759.23, showing a significant increase of 91.43% compared to ¥19,110,813.82 in the previous year[3] - Operating cash flow for Q1 2022 was CNY 36,584,759.23, significantly higher than CNY 19,110,813.82 in Q1 2021, indicating improved cash generation[26] - Cash inflow from operating activities totaled CNY 110,404,760.68 in Q1 2022, down from CNY 125,004,472.30 in Q1 2021[26] - The net cash flow from investment activities was -236,853,601.57 CNY, compared to a positive cash flow of 99,365,015.00 CNY in the previous year[28] - The net increase in cash and cash equivalents for the quarter was -200,392,800.84 CNY, compared to an increase of 118,475,828.82 CNY in the same period last year[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,063,165,160.19, a 2.16% increase from ¥1,040,729,235.00 at the end of the previous year[3] - Total current assets were CNY 718,361,995.97, down from CNY 752,589,813.41, indicating a decrease of about 4.5%[20] - The company's accounts receivable stood at CNY 100,564,442.48, down from CNY 115,087,170.46, reflecting a decrease of approximately 12.7%[19] - Total liabilities decreased to CNY 71,015,536.93 in Q1 2022 from CNY 73,332,468.79 in Q1 2021, a reduction of 3.2%[22] - Non-current assets totaled CNY 344,803,164.22, up from CNY 288,139,421.59, showing an increase of approximately 19.6%[20] Shareholder Information - The company approved the grant of 324,000 restricted stock units to six incentive targets on January 27, 2022[17] - The total number of shares held by the top ten unrestricted shareholders includes 2,999,940 shares held by China Ping An Life Insurance Co., Ltd.[16] - The company reported a total of 95,437,413 shares under lock-up agreements as of the end of the reporting period[16] - The company plans to lift the lock-up on certain shares on July 27, 2023, affecting 62,000,000 shares held by specific shareholders[15] Other Financial Metrics - Basic earnings per share rose to ¥0.16, up 6.67% from ¥0.15 in the same quarter last year[3] - The weighted average return on equity was 2.39%, slightly up from 2.29% in the previous year[3] - Research and development expenses increased to CNY 7,635,949.69 in Q1 2022, compared to CNY 6,362,429.11 in Q1 2021, marking a rise of 20%[23] - The company reported a total of ¥3,890,686.95 in non-recurring gains and losses, primarily from government subsidies and fair value changes of financial assets[5] - Cash and cash equivalents decreased to CNY 281,430,579.21 from CNY 481,823,380.06, representing a decline of approximately 41.7%[19]